WallStSmart

ANI Pharmaceuticals Inc (ANIP)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1477% more annual revenue ($14.56B vs $923.71M). ANIP leads profitability with a 10.0% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 0.14. ANIP earns a higher WallStSmart Score of 69/100 (B-).

ANIP

Strong Buy

69

out of 100

Grade: B-

Growth: 9.3Profit: 7.0Value: 5.7Quality: 7.0
Piotroski: 4/9Altman Z: 1.61

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 0.55

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANIP2 strengths · Avg: 9.0/10
EPS GrowthGrowth
86.1%10/10

Earnings expanding 86.1% YoY

Revenue GrowthGrowth
20.5%8/10

Revenue surging 20.5% year-over-year

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Areas to Watch

ANIP2 concerns · Avg: 3.5/10
Altman Z-ScoreHealth
1.614/10

Distress zone — elevated risk

Market CapQuality
$1.78B3/10

Smaller company, higher risk/reward

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ANIP

The strongest argument for ANIP centers on EPS Growth, Revenue Growth. Revenue growth of 20.5% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : ANIP

The primary concerns for ANIP are Altman Z-Score, Market Cap.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ANIP profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.90 — expect wider price swings.

ANIP is growing revenue faster at 20.5% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Bottom Line

ANIP scores higher overall (69/100 vs 50/100) and 20.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ANI Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?